Literature DB >> 24726726

Molecular insights into NF2/Merlin tumor suppressor function.

Jonathan Cooper1, Filippo G Giancotti2.   

Abstract

The FERM domain protein Merlin, encoded by the NF2 tumor suppressor gene, regulates cell proliferation in response to adhesive signaling. The growth inhibitory function of Merlin is induced by intercellular adhesion and inactivated by joint integrin/receptor tyrosine kinase signaling. Merlin contributes to the formation of cell junctions in polarized tissues, activates anti-mitogenic signaling at tight-junctions, and inhibits oncogenic gene expression. Thus, inactivation of Merlin causes uncontrolled mitogenic signaling and tumorigenesis. Merlin's predominant tumor suppressive functions are attributable to its control of oncogenic gene expression through regulation of Hippo signaling. Notably, Merlin translocates to the nucleus where it directly inhibits the CRL4(DCAF1) E3 ubiquitin ligase, thereby suppressing inhibition of the Lats kinases. A dichotomy in NF2 function has emerged whereby Merlin acts at the cell cortex to organize cell junctions and propagate anti-mitogenic signaling, whereas it inhibits oncogenic gene expression through the inhibition of CRL4(DCAF1) and activation of Hippo signaling. The biochemical events underlying Merlin's normal function and tumor suppressive activity will be discussed in this Review, with emphasis on recent discoveries that have greatly influenced our understanding of Merlin biology.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRL4 E3 ubiquitin ligase; Contact inhibition; DDB1 and Cul4-Associated Factor 1; Hippo signaling pathway; Merlin; Neurofibromatosis Type 2

Mesh:

Substances:

Year:  2014        PMID: 24726726      PMCID: PMC4111995          DOI: 10.1016/j.febslet.2014.04.001

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  130 in total

1.  Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation.

Authors:  J Q Cheng; W C Lee; M A Klein; G Z Cheng; S C Jhanwar; J R Testa
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

2.  The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells.

Authors:  Mira Ernkvist; Nathalie Luna Persson; Stéphane Audebert; Patrick Lecine; Indranil Sinha; Miaoliang Liu; Marc Schlueter; Arie Horowitz; Karin Aase; Thomas Weide; Jean-Paul Borg; Arindam Majumdar; Lars Holmgren
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

Review 3.  Size control in animal development.

Authors:  I Conlon; M Raff
Journal:  Cell       Date:  1999-01-22       Impact factor: 41.582

4.  Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin.

Authors:  Masashi Okada; Yanru Wang; Sung-Wuk Jang; Xiaoling Tang; Luca M Neri; Keqiang Ye
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

5.  Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation.

Authors:  Xiaoling Tang; Sung-Wuk Jang; Xuerong Wang; Zhixue Liu; Scott M Bahr; Shi-Yong Sun; Daniel Brat; David H Gutmann; Keqiang Ye
Journal:  Nat Cell Biol       Date:  2007-09-23       Impact factor: 28.824

6.  Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton.

Authors:  M Laulajainen; T Muranen; O Carpén; M Grönholm
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

7.  Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.

Authors:  Sylwia Ammoun; Christine Flaiz; Natalia Ristic; Jennifer Schuldt; C Oliver Hanemann
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease.

Authors:  Sakura Saburi; Ian Hester; Evelyne Fischer; Marco Pontoglio; Vera Eremina; Manfred Gessler; Sue E Quaggin; Robert Harrison; Richard Mount; Helen McNeill
Journal:  Nat Genet       Date:  2008-07-06       Impact factor: 38.330

9.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

10.  Merlin is a potent inhibitor of glioma growth.

Authors:  Ying-Ka Ingar Lau; Lucas B Murray; Sean S Houshmandi; Yin Xu; David H Gutmann; Qin Yu
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more
  68 in total

1.  Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling.

Authors:  Ming Quan; Jiujie Cui; Tian Xia; Zhiliang Jia; Dacheng Xie; Daoyan Wei; Suyun Huang; Qian Huang; Shaojiang Zheng; Keping Xie
Journal:  Cancer Res       Date:  2015-10-19       Impact factor: 12.701

2.  Merlin's wizardry guides cohesive migration.

Authors:  Ansgar Zoch; Helen Morrison
Journal:  Nat Cell Biol       Date:  2015-03       Impact factor: 28.824

3.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

4.  Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Authors:  Zhiqiang Li; Pedram Razavi; Qing Li; Weiyi Toy; Bo Liu; Christina Ping; Wilson Hsieh; Francisco Sanchez-Vega; David N Brown; Arnaud F Da Cruz Paula; Luc Morris; Pier Selenica; Emily Eichenberger; Ronglai Shen; Nikolaus Schultz; Neal Rosen; Maurizio Scaltriti; Edi Brogi; Jose Baselga; Jorge S Reis-Filho; Sarat Chandarlapaty
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

5.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

Review 6.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 7.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 8.  The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.

Authors:  Manami Kodaka; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2014-09-30       Impact factor: 9.261

9.  Nf2 fine-tunes proliferation and tissue alignment during closure of the optic fissure in the embryonic mouse eye.

Authors:  Wesley R Sun; Sara Ramirez; Kelly E Spiller; Yan Zhao; Sabine Fuhrmann
Journal:  Hum Mol Genet       Date:  2020-12-18       Impact factor: 6.150

Review 10.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.